Abstract

Inflammation is now known to play a significant role in tumour growth and progression. It is also difficult to adequately quantify systemic inflammation and the resulting localized effects in cancer. Here, we use experimental data to infer the possible contributions of inflammation in a mouse model of cancer. The model is validated by predicting tumour growth under anti-inflammatory treatments, and combination cancer therapies are explored. We then extend the model to consider simultaneous tumour implants at two distinct sites, which experimentally was shown to result in one large and one small tumour. We use this model to examine the role inflammation may play in the growth rate separation. Finally, we use this predictive two-tumour model to explore implications of inflammation on metastases, surgical removal of the primary and adjuvant anti-inflammatory treatments. This work suggests that improved tumour control can be obtained by targeting both the cancer and host, through anti-inflammatory treatments, including reduced metastatic burden post-surgical removal of primary tumours.

中文翻译：

---

数学建模炎症作为肿瘤生长的促进剂。

摘要

现在已知炎症在肿瘤生长和进展中起重要作用。也很难充分量化全身炎症和由此产生的癌症局部效应。在这里，我们使用实验数据来推断炎症在癌症小鼠模型中的可能贡献。该模型通过预测抗炎治疗下的肿瘤生长来验证，并探索了联合癌症治疗。然后我们扩展模型以考虑在两个不同部位同时植入肿瘤，实验表明这会导致一个大肿瘤和一个小肿瘤。我们使用该模型来检查炎症在增长率分离中可能发挥的作用。最后，我们使用这种预测性双肿瘤模型来探索炎症对转移的影响，手术切除主要和辅助抗炎治疗。这项工作表明，通过抗炎治疗，包括减少手术后切除原发肿瘤的转移负担，可以通过靶向癌症和宿主来改善肿瘤控制。